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Abstract
Chronic dermal wounds are a devastating problem, which disproportionally affect in-
dividuals with conditions such as diabetes, paralysis, or simply old age. These wounds 
are extremely challenging to treat due to a heterogeneous combination of causative 
factors, creating a substantial burden on healthcare systems worldwide. Despite their 
large impact, there is currently a startling lack of options for effectively treating the 
underlying biological changes that occur within the wounds. Biomaterials possess an 
enticing ability to provide new comprehensive approaches to healing these devastat-
ing wounds; advanced wound dressings are now being developed that enable the 
ability to coordinate temporal delivery of multiple therapeutics, protect sensitive bio-
logics from degradation, and provide supportive matrices that encourage the growth 
of tissue. This positions biomaterials as a potential “conductor” of wound repair, allow-
ing them to simultaneously address numerous barriers to healing, and in turn providing 
a promising pathway to innovative new technologies for driving successful healing.
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1  | CHRONIC SKIN 
WOUNDS ARE A MAJOR BURDEN ON 
INDIVIDUALS AND SOCIETY
Chronic skin ulcerations such as venous, decubitus or diabetic ulcers 
have a large impact on societies in both developed and developing 
countries around the world.[1] In the UK, they affect an estimated 
1% of the total UK adult population, and as high as 5% of the UK 
population over 65.[s1] These devastating wounds have an enor-
mous negative impact on an individual’s quality of life, leading to 
loss of mobility and sleep deprivation and contributing to increased 
risk of amputation, anxiety, and depression.[s2-s6] Looking solely at 
diabetic foot ulcers (DFU), diabetic individuals possess a 23- fold in-
crease in the rate of amputation following ulceration compared with 
non- diabetics, with up to 85% of amputations preceded by DFUs.[s6] 
Moreover, the 5- year mortality rates associated with DFUs or DFU- 
related amputations have been found to be as high as or higher than 
those of breast and prostate cancer.[s7] With an increasing frequency 
of diabetes and obesity, along with an ageing population, these val-
ues are only expected to rise without any further innovations for 
treatment.
2  | BIOMATERIALS ENABLE NOVEL 
THERAPEUTIC APPROACHES
Despite the large impact of these wounds, there are surprisingly few 
options available for treating them that take advantage of recent 
insights from the laboratory. While conventional strategies such as 
debridement, negative pressure therapy, and offloading orthotics can 
lead to successful wound closure in many patients,[s8] these treatments 
are ineffective for a significant number of individuals. Many times this 
resistance to treatment may stem from underlying biological changes 
that affect the ability of cells within the skin to properly carry out 
the process of tissue repair;[s9] cells isolated from DFUs have been 
shown to display differences in their response to growth factors,[s10] 
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proliferation rates,[s11] composition of the extracellular matrix (ECM) 
they deposit,[s12] levels of proteases produced,[s13,s14] and regulatory 
RNA molecules such as microRNAs.[s15]
The ability to correct these biological abnormalities within the 
wound microenvironment has been actively explored as a key strategy 
for developing new therapeutic options. Unfortunately, the transla-
tion of pharmaceutical- based approaches from the bench to bedside 
over the past two decades has been a splendid graveyard of failures. 
While this may seem dire in terms of future prospects, the field of 
tissue engineering and biomaterials has slowly played a more active 
and important role towards achieving translational success.[2,s16-s24] 
Significant emphasis has been put on the development of bioengi-
neered skin replacements, such as decellularised matrices, living skin 
constructs and degradable polymeric scaffolds that mimic multiple 
features of the native ECM and allow modulation of the matrix within 
the wound bed.[s25-s28] Such scaffolds, whether natural or synthetic, 
have porous microstructures tagged with cell- binding sites to support 
the infiltration and adhesion of cells, allow diffusion of nutrients and 
metabolites, have controllable degradation mechanisms, and can act 
as reservoirs to retain bioactive agents that stimulate innate tissue 
repair mechanisms[2,s24,s29] (Figure 1). In this way, they act as a sup-
port to the native wound microenvironment to regulate cell behaviour, 
such as the proliferation, migration, and differentiation of cells within 
the wound, providing instructive cues that are crucial for efficient 
wound closure.
When aiming to synthesise biomaterial scaffolds, there are many 
avenues that are available to pick from depending on the required 
functionality of the scaffold. For instance, in one study ECM- mimicking 
scaffolds have been developed to encourage cell migration.[3] These 
microporous scaffolds are electrospun from collagen I (col) and poly 
(ε- caprolactone) (PCL) in a 70:30 ratio, with pores of 160 μm diameter 
subsequently being introduced mechanically throughout the thickness 
of the scaffold. This architecture creates an optimal mesh that fos-
ters fibroblast infiltration, attachment, and proliferation in vitro. The 
authors demonstrated that primary human fibroblasts isolated from 
neonatal foreskin migrate into the scaffolds and secrete native ECM 
molecules, such as collagen and fibronectin, while also remodelling the 
scaffold to mimic the normal dermal matrix. When implanted into full- 
thickness rat skin wounds, these 70:30 col/PCL scaffolds stimulated 
more rapid and effective wound healing compared with scaffolds lack-
ing micropores or sham wounds.
In other work, researchers demonstrated that a dextran- based hy-
drogel scaffold consisting of UV- cross- linked dextran- allyl isocyanate- 
ethylamine and polyethylene glycol diacrylate polymers are able to 
promote regenerative healing in a third- degree mouse burn wound 
model.[4] This hydrogel, with no additional growth factors, cytokines, 
or cells, facilitates early infiltration by inflammatory cells that leads to 
rapid degradation of the hydrogel, in turn promoting significant neo-
vascularisation by day 7, followed by complete skin regeneration at 
3 weeks postwounding. When recently tested in a porcine burn wound 
model, the same hydrogel promoted tissue regeneration through fast 
neovascularisation, formation of ECM- rich granulation tissue, and en-
hanced re- epithelialisation of the wound area compared with control 
dressings.[s30] Other work by the group has given rise to a hypoxia- 
inducible hydrogel that guides vascular morphogenesis in vitro and 
in vivo by establishing precise oxygen gradients generated within the 
hydrogel.[5] Although not currently used for the treatment of chronic 
wounds, biomaterials that can manipulate local oxygen concentration 
within ischaemic diabetic and venous ulcers are a potentially interest-
ing approach for promoting wound resolution.
While these examples provide options for creating matrices that 
manipulate the local wound environment and provide a scaffold for 
infiltrating cells, it may be necessary to also deliver sensitive biologics, 
such as growth factors or nucleic acids, to fully address the biological 
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deficiencies observed in chronic wounds (Figure 2). These biological 
agents require complex delivery mechanisms that protect them from 
degradation by enzymes in the hostile wound environment, control 
the rate of therapeutic release to present an extended physiologically 
relevant dosage, and facilitate efficient localised therapy at the appro-
priate site of action. Assuming these hurdles are overcome, the chal-
lenge of treating wounds that display such heterogeneous changes 
using a single therapeutic is still a daunting prospect. These wounds 
likely require advanced wound dressings that can coordinate the tem-
poral delivery of multiple therapeutics into the wound bed. In doing 
so, each therapeutic can build on the impact of preceding ones and 
further synergise with each other for improved efficacy.
However, traditional delivery platforms such as creams (e.g. beca-
plermin), sprays (e.g. trafermin) and injections (e.g. Heberprot- P) are 
unlikely to provide the control necessary to fully exploit this strategy. 
Using these methods does not enable the ability to easily tune the 
spatiotemporal delivery pattern, resulting in large initial bolus releases 
and high- dosage deliveries that may lead to serious side effects, while 
also requiring a high level of patient compliance that many times pres-
ents a significant challenge when treating chronic wounds.[s31,s32]
To overcome some of these barriers, we have recently developed 
a self- assembled coating for wound dressings that enables sustained 
release of multiple active growth factors while allowing indepen-
dent modulation of their individual release kinetics.[6] In this work, 
we incorporated VEGF- 165 and PDGF- BB onto woven nylon wound 
dressings using the layer- by- layer (LbL)[s33] process. Experiments in 
db/db mice demonstrated increased levels of both angiogenesis and 
formation of granulation tissue with the dressings. This was accom-
plished using a total growth factor dose of approximately 150 ng, an 
amount 300 times lower than previously used for the FDA- approved 
becaplermin gel.[s34] Further to this, we demonstrated that the LbL 
technique is able to create wound dressings that facilitate local-
ised release of siRNA targeting MMP- 9 (siMMP- 9) in db/db mice.[7] 
This strategy led to a reduction in MMP- 9 expression and activity 
after 2 weeks of over 75% and 55%, respectively, resulting in dra-
matic improvements in the rate of granulation tissue formation and 
re- epithelialisation.
While these two examples demonstrate the flexibility of a tech-
nique such as LbL, there are many other strategies that have been 
developed to enable efficient delivery of biologics. For instance, re-
cent research has demonstrated that sustained siRNA delivery to 
skin wounds is possible by packaging siRNA molecules within pH- 
responsive polymer nanoparticles composed of 2- dimethylaminoethyl 
methacrylate, which are then incorporated in biodegradable injectable 
polyurethane scaffolds.[8] The nanoparticles protect the siRNA from 
degradation by nucleases and ensure the siRNA is delivered once it 
enters an acidifying endosome (pH 5.8), instead of being released in 
the extracellular milieu. In this study, the delivery platform promoted 
angiogenesis in a balb/c mouse wound model through sustained and 
controlled knockdown of the enzyme prolyl hydroxylase 2, PHD2. 
This resulted in a significant increase in HIF1α- mediated transcrip-
tion of the pro- angiogenic genes VEGF and FGF- 2, in turn leading to a 
280% increase in vessel area at day 33. Recently, the same group has 
demonstrated that PHD2 knockdown via ROS- degradable scaffolds 
also improves wound healing in diabetic mice.[9] These examples to-
gether illustrate how carefully designed biomaterial- based platforms 
have an enormous potential to efficiently target biological changes in 
chronic wounds.
3  | THE PATHWAY FORWARD
There are many interesting biological targets that need further explo-
ration and validation in the context of chronic wound healing, as excit-
ing new developments are constantly being made in this area. Recent 
findings have elucidated an important role of Ephrin- B1 in regulating 
epithelial cell- cell junctions during re- epithelialisation, with clinical 
non- healing chronic wounds displaying strong upregulation.[s35] In 
other research, it has been shown that persistent PKCδ expression 
inhibits insulin signalling in fibroblasts from type 1 diabetic wounds, 
with siRNA knockdown of PKCδ resulting in increased levels of p- AKT, 
VEGF expression and rate of wound healing in vivo.[s36] Finally, sus-
tained release of stromal cell- derived factor- 1 (SDF- 1) from an anti-
oxidant thermoresponsive hydrogel has been shown to significantly 
enhance formation of granulation tissue and epithelial maturation in 
non- healing DFUs.[s37]
How these new insights can be integrated into a comprehensive 
therapeutic strategy that builds on extensive prior findings is still un-
known; such a strategy will likely require a combination of proteins, 
nucleic acids, cells, and polymeric scaffolds that act together in a 
concerted manner to synergistically rewire the local wound environ-
ment to drive healing. This is where biomaterials enter the picture as 
an enabling technology that can simultaneously address differential 
delivery needs for each therapeutic (intra- cellular, extracellular), opti-
mise dosing schedules, and provide a supportive extracellular matrix 
for the wound microenvironment. These strategies for treating chronic 
wounds will then likely need to be paired with the development of var-
ious biomarkers that can effectively stratify patient populations into 
treatable cohorts. For instance, patient stratification based on mac-
rophage gene expression,[s38] or potentially by using non- invasive im-
aging of wounds[s39] to identify wounds that are most likely to benefit 
from certain treatment strategies, is crucial for maximising the success 
of advanced therapies.
However, despite these stimulating advances in the field of bio-
materials for wound healing applications, hurdles that still need to be 
addressed include the manufacturability of the materials as the level 
of complexity increases, along with the toxicity and biocompatibility 
of these materials with the host tissue. Care must be taken when de-
signing degradable hydrogels for tissue repair, as these gels can form 
toxic degradation products (e.g., carboxylic acid products derived 
from ester- based degradation mechanisms). Such products have the 
ability to raise the local acidity of the surrounding tissue and trigger 
a pronounced inflammatory response over time;[s40] ideally, biode-
gradable hydrogels will create no detrimental degradation products 
while promoting quality tissue integration and triggering minimal 
immunogenicity.
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Nevertheless, we are excited by the fact that our understanding 
of tissue- biomaterial interplay is growing, insightful new discover-
ies into the biology of wound healing and chronic wounds are being 
continually uncovered around the world,[s41-s51] and progress is being 
made on our ability to design materials that interact with biology 
over time in a bidirectional way. With help from regulatory bodies 
to ease advancement of promising combination therapies for a med-
ical condition with worse survival rates than some cancers, we are 
optimistic that new interventions will soon be developed that will 
have a meaningful effect on reducing the devastating impact chronic 
wounds have on society.
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